This site is intended for health professionals only

FDA approves anti-clotting drug


The US Food and Drug Administration has approved a new drug that can reduce the risk of strokes for patients with irregular heartbeats.

Pradaxa will be available for patients that suffer from atrial fibrillation, a heart problem in which the heart’s chambers do not properly contract.

The previous treatment for atrial fibrillation was the drug Warfarin, which has side effects that include internal bleeding.

Article continues below this sponsored advert
Cogora InRead Image
Explore the latest advances in respiratory care at events delivered by renowned experts from CofE

The FDA approved Pradaxa after a study comparing the two drugs showed that patients taking the newer pill had fewer strokes.

German drugmaker Boehringer Ingelheim produces the drug, which works by stopping an enzyme that is involved in blood clotting.

Copyright Press Association 2010

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine